Sippican Capital Advisors Eli Lilly & CO Transaction History

Sippican Capital Advisors

$130 Million
Q3 2024

A detailed history of Sippican Capital Advisors transactions in Eli Lilly & CO stock. As of the latest transaction made, Sippican Capital Advisors holds 3,444 shares of LLY stock, worth $2.71 Million. This represents 2.34% of its overall portfolio holdings.

Number of Shares

3,444

Previous 3,469 0.72%

Holding current value

$2.71 Million

Previous $3.14 Million 2.83%

% of portfolio

2.34%

Previous 2.69%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$772.14 - $960.02 $19,303 - $24,000	-25 Reduced 0.72%	3,444 $3.05 Million
Q2 2024 Aug 06, 2024	SELL	$724.87 - $909.04 $84,809 - $106,357	-117 Reduced 3.26%	3,469 $3.14 Million
Q1 2024 May 02, 2024	SELL	$592.2 - $792.28 $646,090 - $864,377	-1,091 Reduced 23.33%	3,586 $2.79 Million
Q4 2023 Jan 30, 2024	BUY	$525.19 - $619.13 $441,684 - $520,688	841 Added 21.92%	4,677 $2.73 Million
Q3 2023 Oct 24, 2023	SELL	$434.7 - $599.3 $123,889 - $170,800	-285 Reduced 6.92%	3,836 $2.06 Million
Q2 2023 Aug 15, 2023	SELL	$350.74 - $468.98 $64,536 - $86,292	-184 Reduced 4.27%	4,121 $1.93 Million
Q1 2023 Jul 14, 2023	SELL	$310.63 - $364.82 $46,594 - $54,723	-150 Reduced 3.37%	4,305 $1.48 Million
Q4 2022 Jan 26, 2023	BUY	$321.55 - $374.67 $1,929 - $2,248	6 Added 0.13%	4,455 $0
Q3 2022 Oct 17, 2022	SELL	$296.48 - $337.87 $27,869 - $31,759	-94 Reduced 2.07%	4,449 $1.44 Million
Q2 2022 Jul 19, 2022	SELL	$278.73 - $327.27 $264,236 - $310,251	-948 Reduced 17.26%	4,543 $1.47 Million
Q1 2022 Apr 20, 2022	SELL	$234.69 - $291.66 $31,683 - $39,374	-135 Reduced 2.4%	5,491 $1.57 Million
Q4 2021 Jan 19, 2022	SELL	$224.85 - $279.04 $6,745 - $8,371	-30 Reduced 0.53%	5,626 $1.55 Million
Q3 2021 Oct 20, 2021	SELL	$221.6 - $272.71 $35,456 - $43,633	-160 Reduced 2.75%	5,656 $1.31 Million
Q2 2021 Jul 22, 2021	SELL	$180.55 - $233.54 $3,611 - $4,670	-20 Reduced 0.34%	5,816 $1.34 Million
Q1 2021 Apr 15, 2021	SELL	$164.32 - $212.72 $22,676 - $29,355	-138 Reduced 2.31%	5,836 $1.09 Million
Q4 2020 Jan 21, 2021	SELL	$130.46 - $172.63 $50,879 - $67,325	-390 Reduced 6.13%	5,974 $1.01 Million
Q3 2020 Oct 23, 2020	BUY	$146.22 - $169.13 $7,311 - $8,456	50 Added 0.79%	6,364 $942,000
Q2 2020 Jul 15, 2020	SELL	$136.42 - $164.18 $139,284 - $167,627	-1,021 Reduced 13.92%	6,314 $1.04 Million
Q1 2020 Apr 16, 2020	SELL	$119.05 - $147.35 $136,193 - $168,568	-1,144 Reduced 13.49%	7,335 $1.02 Million
Q4 2019 Jan 21, 2020	SELL	$106.92 - $132.43 $106 - $132	-1 Reduced 0.01%	8,479 $1.11 Million
Q3 2019 Oct 17, 2019	SELL	$106.79 - $116.16 $67,811 - $73,761	-635 Reduced 6.97%	8,480 $948,000
Q2 2019 Jul 17, 2019	SELL	$110.79 - $129.32 $79,325 - $92,593	-716 Reduced 7.28%	9,115 $1.01 Million
Q1 2019 Apr 17, 2019	SELL	$111.31 - $131.02 $302,095 - $355,588	-2,714 Reduced 21.63%	9,831 $1.28 Million
Q4 2018 Jan 16, 2019	SELL	$105.9 - $118.64 $130,786 - $146,520	-1,235 Reduced 8.96%	12,545 $1.45 Million
Q3 2018 Nov 13, 2018	SELL	$85.86 - $107.31 $158,154 - $197,665	-1,842 Reduced 11.79%	13,780 $1.52 Million
Q2 2018 Jul 17, 2018	SELL	$75.7 - $86.88 $66,237 - $76,020	-875 Reduced 5.3%	15,622 $1.33 Million
Q1 2018 Apr 24, 2018	BUY	$74.21 - $87.6 $816 - $963	11 Added 0.07%	16,497 $1.28 Million
Q4 2017 Jan 17, 2018	SELL	$81.94 - $87.89 $8,194 - $8,789	-100 Reduced 0.6%	16,486 $1.39 Million
Q3 2017 Oct 30, 2017	BUY	$77.07 - $85.54 $1.28 Million - $1.42 Million	16,586	16,586 $1.42 Million

Others Institutions Holding LLY

# of Institutions

4,007

Shares Held

752M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $749B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sippican Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Sippican Capital Advisors with notifications on news.

Account

Sippican Capital Advisors Eli Lilly & CO Transaction History